Evidence map›Paper›PMID 22054892›Full record

ReviewClinics in chest medicine2011

Gene therapy for lung neoplasms.

Anil Vachani, Edmund Moon, Elliot Wakeam, Andrew R Haas, Daniel H Sterman, Steven M Albelda

Abstract readReview
In one paragraph

Review in Clinics in chest medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 38 citations in OpenAlex.

  1. Bronchoscopic intratumoural therapies for non-small cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  2. Article
  3. Article
  4. Article
  5. Suicide Gene Therapy for Cancer - Current Strategies.Journal of genetic syndromes & gene therapy · 2013
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anil VachaniDivision of Pulmonary, Allergy & Critical Care Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Edmund Moon
Elliot Wakeam
Andrew R Haas
Daniel H Sterman
Steven M Albelda
University of Pennsylvania · US

Funding

VECTOR DEVELOPMENT /PRECLINICAL TESTINGP01CA066726 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KALOS, MICHAEL D · 1995 to 2016
$18.2M
Molecular epidemiology of lung cancerK07CA111952 · NCI · UNIVERSITY OF PENNSYLVANIA · PI VACHANI, ANIL · 2006 to 2010
$692k
NCI NIH HHS K07 CA111952NCI NIH HHS P01 CA066726NCI NIH HHS P01 CA66726
6 · The paper itself

Abstract

Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.

Indexed as

Gene Expression Regulation, NeoplasticGenetic TherapyGenetic VectorsHumansImmunotherapyLung NeoplasmsMesothelioma

Identifiers

PMID22054892
PMCPMC3210443
OpenAlexW1973844023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.